Critical Importance of In Vivo Amoxicillin and Cefotaxime Concentrations for Synergy in Treatment of Experimental Enterococcus faecalis Endocarditis | Zendy

Olivier JoinLambert | Zendy; JeanLuc Mainardi | Zendy; Catherine Cuvelier | Zendy; Sophie Dautrey | Zendy; Robert Farinotti | Zendy; B. Fantin | Zendy; Claude Carbón | Zendy

Open Access

Critical Importance of In Vivo Amoxicillin and Cefotaxime Concentrations for Synergy in Treatment of Experimental Enterococcus faecalis Endocarditis

Author(s) -

Olivier JoinLambert,

JeanLuc Mainardi,

Catherine Cuvelier,

Sophie Dautrey,

Robert Farinotti,

B. Fantin,

Claude Carbón

Publication year - 1998

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.42.2.468

Subject(s) - cefotaxime , enterococcus faecalis , amoxicillin , in vivo , microbiology and biotechnology , endocarditis , in vitro , antibacterial agent , antibiotics , enterococcus , chemistry , medicine , pharmacology , biology , surgery , bacteria , biochemistry , staphylococcus aureus , genetics

The synergy between amoxicillin and cefotaxime against two strains ofEnterococcus faecalis (JH2-2 and 6370) in vitro and in rabbit endocarditis was investigated. In vitro synergy was obtained only when amoxicillin concentrations were below the MBC and when cefotaxime concentrations were above 1 μg/ml. No synergy was observed in vivo, because of the short period of time during which these pharmacologic requirements were achieved.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research